August 21, 2024 10:47 AM EDTUpdated 03:40 PM
News Briefing

Van­dria rais­es an­oth­er $10M; Nykode ends Phase 2 tri­al in cer­vi­cal can­cer

ENDPOINTS

Plus, news about Reten­sion Phar­ma­ceu­ti­cals:

Van­dria tops up Se­ries A with an­oth­er $10M: The Swiss biotech in­creased its round to­tal to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times